Who are Betmiga®'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Midamor, Spironolacton (hexalacton(R)), Phase C: Spironolactone, Spironolactone and furosemide, spironolactone + furosemide, Amlodipine, Telmisartan, Amiloride Compound , Simvastatin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/betmiga.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Betmiga® — Competitive Intelligence Brief

Betmiga® (Betmiga®) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Potassium-sparing diuretic. Area: Urology.

phase 2 Potassium-sparing diuretic Urology Small molecule Live · refreshed every 30 min

Target snapshot

Betmiga® (Betmiga®) — Astellas Pharma Europe Ltd.. Betmiba works by increasing the levels of magnesium in the urine, which helps to prevent kidney stones.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Betmiga® TARGET	Betmiga®	Astellas Pharma Europe Ltd.	phase 2	Potassium-sparing diuretic
Midamor	AMILORIDE	Padagis Us	marketed	Potassium-sparing Diuretic	Amiloride-sensitive sodium channel, ENaC	1981-01-01
Spironolacton (hexalacton(R))	Spironolacton (hexalacton(R))	Steno Diabetes Center Copenhagen	marketed	Potassium-sparing diuretic; aldosterone antagonist	Mineralocorticoid receptor (MR)
Phase C: Spironolactone	Phase C: Spironolactone	National Institute of Cardiology, Warsaw, Poland	marketed	Potassium-sparing diuretic; Aldosterone antagonist	Mineralocorticoid receptor (MR)
Spironolactone and furosemide	Spironolactone and furosemide	University of Padova	marketed	Combination diuretic (potassium-sparing diuretic + loop diuretic)	Aldosterone receptor (spironolactone); Na-K-Cl cotransporter (furosemide)
spironolactone + furosemide	spironolactone + furosemide	Tottori University Hospital	marketed	Diuretic combination (potassium-sparing diuretic + loop diuretic)	Aldosterone receptor (spironolactone); Na-K-2Cl cotransporter (furosemide)
Amlodipine, Telmisartan, Amiloride Compound , Simvastatin	Amlodipine, Telmisartan, Amiloride Compound , Simvastatin	Chinese Academy of Medical Sciences, Fuwai Hospital	marketed	Antihypertensive combination (calcium channel blocker + angiotensin II receptor blocker + potassium-sparing diuretic + statin)	L-type calcium channels, AT1 angiotensin II receptor, epithelial sodium channels (ENaC), HMG-CoA reductase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Potassium-sparing diuretic class)

Assistance Publique - Hôpitaux de Paris · 1 drug in this class
Astellas Pharma Europe Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Betmiga® — Competitive Intelligence Brief. https://druglandscape.com/ci/betmiga. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab